Histamine in cancer immunotherapy

References

• Rosenberg S A, Lotze M T, Muul L M. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or interleukin-2 alone. N Engl J Med 1987; 316: 889–97
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T, Yang J C, Aebersold P M. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–85
   PubMed Web of Science ®Google Scholar
• Gutterman J U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 15: 1198–205
   Google Scholar
• Bukowski R M, Goodman R, Crawford E D. A phase II study of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1989; 7: 477–85
   PubMedGoogle Scholar
• Dorr R T. Interferon-alpha in malignant and viral diseases. A review. Drugs 1993; 45: 177–211
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187–376
   PubMed Web of Science ®Google Scholar
• Friedman R, Vogel S N. Interferons with special emphasis on the immune; system. Adv Immunol 1983; 34: 97–121
   PubMed Web of Science ®Google Scholar
• Billington D C. Angiogenesis and its inhibition: potential new therapies in oncology and nonneoplastic diseases. Drug Des Discov 1991; 8: 3–35
   PubMedGoogle Scholar
• Einhorn S, Blomgren H, Strander H. Interferon and spontaneous cytotoxicity in man. I Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer 1978; 22: 405–9
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Yoshie O, Aso H, Ebina T, Ishida N. Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon alpha A/D. Jpn J Cancer Res 1986; 77: 80–4
   PubMedGoogle Scholar
• Fresa K L, Murasko D M. Role of natural killer cells in the mechanism of the antitumor effect of interferon on Moloney sarcoma virus-transformed cells. Cancer Res 1986; 46: 81–8
   PubMed Web of Science ®Google Scholar
• Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant inter-leukin-2-activated killer-sensitive and -resistant murine tumors. J Biol Response Mod 1989; 8: 676–90
   PubMedGoogle Scholar
• Brunda M J, Bellantoni D, Sulich V. In vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40: 365–41
   PubMed Web of Science ®Google Scholar
• Alexander P, Eccles S A, Gauci C L. The significance of macrophages in human and experimental tumors. Ann N Y Acad Sci 1976; 276: 124–33
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Kjellson B, Hermodsson S. Monocyte-induced down-modulation of CD16 and CD56 Ag expression on human natural killer cells and its regulation by histamine IE-receptors. Cell Immunol 1991; 138: 44–54
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol 1991; 34: 741–52
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Monocyte-mediated suppression of IL-2-induced NK cell activation: regulation by serotonin 5-HT1A receptors. Scand J Immunol 1990; 32: 183–92
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allergy Appl Immunol 1990; 92: 379–89
   PubMedGoogle Scholar
• Hellstrand K, Kylefjord H, Asea A, Hermodsson S. Regulation of the NK-cell response to IFN-a-gamma by biogenic amines. J Interferon Res 1992; 12: 199–206
   PubMedGoogle Scholar
• Hellstrand K, Asea A, Hermodsson S. Histamin-ergic regulation of NK-cells: role of monocyte-derived, reactive oxygen metabolites. J Immunol 1994; 153: 4940–7
   PubMed Web of Science ®Google Scholar
• Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156: 42–7
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes and natural killer cells. J Leukocyte Biol 1994; 55: 392–7
   PubMed Web of Science ®Google Scholar
• Hansson M, Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis. Scand J Immunol 1996; 42: 193–6
   Web of Science ®Google Scholar
• Brocker E B, Zwadlo G, Suter L, Brune M, Sorg C. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother 1987; 25: 81–6
   PubMed Web of Science ®Google Scholar
• Allen C, Hogg N. Elevation of infiltrating mono-nuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 1987; 78: 465–70
   PubMed Web of Science ®Google Scholar
• Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308–13
   PubMed Web of Science ®Google Scholar
• Matsuda M, Petersson M, Lenkei R, Taupin J L, Magnusson I, Mellstedt H, Anderson P, Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Intl J Cancer 1995; 61: 765–72
   PubMed Web of Science ®Google Scholar
• Burde R, Buschauer A, Seifert R. Characterization of histamine H2-receptors in human neutrophils with a series of guanidine analogues of impromidine. Are cell type-specific H2-receptors involved in the regulation of NADPH oxidase?. Naumyn Schmiedebergs Arch Pharmacol 1990; 341: 455–61
   PubMed Web of Science ®Google Scholar
• Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br J Haematol 1996; 92: 620–6
   PubMed Web of Science ®Google Scholar
• Brune M, Hansson M, Mellqvist U H, Hermodsson S, Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996, In press
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Histamine H2 receptor mediated regulation of human natural killer cell cytotoxicity. J Immunol 1986; 137: 656–60
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J Immunol 1987; 139: 869–75
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Mule J J, Spiess P J, Reichert M, Schwarz S L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169–88
   PubMed Web of Science ®Google Scholar
• Mule J J, Yang J C, Lafreniere R, Shu S, Rosenberg S A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987; 139: 285–99
   PubMed Web of Science ®Google Scholar
• Lotze M T, Rosenberg S A. Interleukin 2 as a pharmacologic reagent. Interleukin-2, K A Smith. Academic Press, San Diego 1988; 237–94
   Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol 1990; 145: 4365–70
   PubMed Web of Science ®Google Scholar
• Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer-cell-mediated clearance of tumor cells in mice. Scand J Immunol 1996; 43: 9–15
   PubMed Web of Science ®Google Scholar
• Oldham R K, Blumenschein G, Schwartzberg L. Combination biotherapy utilizing interleukin-2 and a interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 1992; 4: 4–9
   PubMedGoogle Scholar
• Whitehead R P, Kopecky K, Samson M K. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 1250–3
   PubMed Web of Science ®Google Scholar
• Whitehead R P, Figlin R, Citron M L. A phase II study of concomitant recombinant interleukin 2 (IL-2) and recombinant interferon a 2A (a-IFN-α) in patients with disseminated malignant melanoma. Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1990; 9: A1088
   Google Scholar
• Goodman L S, Gilman A. The pharmacological basis of therapeutics5th ed.
   Google Scholar
• Hellstrand K, Naredi P, Lindnér P, Lundholm K, Hermodsson S, Rudenstam C M, et al. Histamine in immunotherapy of advanced melanoma. Cancer Immunol Immunother 1994; 39: 416–19
   PubMed Web of Science ®Google Scholar
• Carneskog J, Brune M, Hellstrand K. Prognosis of de novo AML in second or subsequent complete remission, In manuscript
   Google Scholar
• Thalhammer F, Geissler K, Jager U, Kyrle P A, Pabinger I, Mitterbauer M, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996; 72: 216–22
   PubMed Web of Science ®Google Scholar
• Shepherd J D, Jacky E, Grathwohl A, Helbig W, Maranchini D, Zittoun R, et al. Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br J Haematol 1994; S87: 205
   Google Scholar
• Bergmann L, Heil G, Kolbe K, Lengfelder E, Puzicha E, Martin H, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16: 271–9
   PubMed Web of Science ®Google Scholar
• Vogler W R. Strategies in the treatment of acute myelogenous leukemia. Leuk Res 1992; 16: 1143–53
   PubMed Web of Science ®Google Scholar
• Mastrianni D M, Tung N M, Tenen D G. Acute myelogenous leukemia: current treatment and future directions. Am J Med 1992; 92: 286–95
   PubMed Web of Science ®Google Scholar
• Swansbury G J, Lawler S D, Alimena G, Arthur D, Berger R, Van den Berghe H, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1–7
   PubMed Web of Science ®Google Scholar
• Caron P C, Scheinberg D A. Immunotherapy for acute leukemias. Curr Opin Oncol 1994; 6: 14–22
   PubMedGoogle Scholar
• Archimbaud E, Bailly M, Doré J F. Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukemia in complete remission and its clinical relevance. Br J Haematol 1991; 77: 328–34
   PubMed Web of Science ®Google Scholar
• Lauria F, Raspadori D, Rondelli D, Ventura M A, Foa R. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994; 8: 724–8
   PubMed Web of Science ®Google Scholar
• Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158–63
   PubMed Web of Science ®Google Scholar
• Blaise D, Altai A, Pico J L, Reiffers J, Stoppa A M, Bellanger C, et al. Impact of recombinant IL-2 (rIL-2) after autologous BMT in 50 patients with CR1 acute leukemia. Br J Haematol 1996; S19: 122
   Google Scholar
• MacDonald D, Jiang Y Z, Gordon A A. Recombinant IL 2 for acute myeloid leukemia in first complete remission: a pilot study. Leuk Res 1990; 14: 967–73
   PubMed Web of Science ®Google Scholar